NCT05341492招募中早期 1 期
A Single-arm, Open, Exploratory Clinical Study Evaluating the Safety and Efficacy of EGFR/B7H3 CAR-T in Patients With EGFR/ B7H3-positive Advanced Solid Tumors (Lung and Triple-negative Breast Cancer)
Second Affiliated Hospital of Guangzhou Medical University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年5月1日最近更新:
适应症
试验速览
- 阶段
- 早期 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Safety by Common Terminology Criteria for Adverse Events (CTCAE) V5.0
研究概览
简要总结
This study is a single-arm, open, exploratory clinical study to evaluate the safety and efficacy of EGFR/B7H3 CAR-T in patients with EGFR/ B7H3-positive advanced solid tumors (lung cancer and triple-negative breast cancer)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.All subjects or legal guardians must sign the informed consent form approved by the ethics committee in writing before starting any screening procedure;
- •2.18 Years to 75 Years, Histologically or cytologically confirmed Routine treatment of patients with advanced lung cancer and triple-negative breast cancer(Including TKI treatment failure patients);
- •3.EGFR/B7H3 expression was confirmed positive in tumor site by immunohistochemical test within 3 months before signing the informed consent form;
- •4.According to RECIST version 1.1 of solid tumor efficacy evaluation criteria, there should be at least one measurable lesion during screening period (results are available within one month prior to screening period) ;
- •5.Expected survival time ≥ 12 weeks;
- •6.The Eastern oncology group strength status score (ECOG) was 0-1;
- •7.Adequate organ function: alanine aminotransferase, aspartate aminotransferase (ALT, AST) < 3 times of normal value, total bilirubin (TBiL) < 1.5 times of normal value, serum creatinine (SCr) < 1.5 times of normal value;
- •8.The hemodynamics determined by echocardiography or multichannel radionuclide angiography(MUGA) are stable and the left ventricular ejection fraction (LVEF)≥50%;
- •9.Have sufficient bone marrow reserves (subjects can meet this requirement through blood transfusion), defined as: The number of white blood cells should not be less than 1 × 10^9/L;Platelet≥100 x 10^9/L; Hemoglobin ≥100 g/L;
- •10.Women of childbearing age and all male subjects must agree to use effective contraceptive methods for at least 52 weeks after EGFR CAR-T infusion, and until two consecutive PCR tests show that CAR-T cells are no longer present in the body.
排除标准
- •1.Uncontrolled hypertension (> 160/95), unstable coronary artery disease confirmed by uncontrolled arrhythmia, unstable angina pectoris, decompensated congestive heart failure (> New York Heart Association Class II), or myocardial infarction within 6 months prior to cell infusion;
- •2.Patients with severe liver and kidney dysfunction or consciousness disorder;
- •3.Patients who received antitumor chemotherapy other than lymphocyte clearance chemotherapy within 14 days prior to CAR T infusion;
- •4.Patients who received other study drugs within 14 days prior to infusion;
- •5. Patients treated with radiotherapy or TKI within 2 weeks prior to infusion;
- •6. Patients with active hepatitis B: HBV DNA>1000IU/mL;
- •7. HIV antibody, hepatitis C antibody, treponema pallidum antibody positive patients;
- •8. Sputum smears and patients who test positive for T cells of tuberculosis infection
- •9.Patients with interstitial lung disease or pneumonia;
- •10.patients with uncontrolled acute life-threatening bacterial, viral or fungal infection (e.g. positive blood culture ≤72 hours prior to infusion);
- •11.Patients with central nervous primary tumor or central metastasis solid tumor (patients with stable treatment for more than 4 weeks after brain metastasis or patients with asymptomatic brain metastasis without treatment are excluded from this range), and patients with pericardial metastasis accompanied by large pericardial effusion.
- •12.Patients with a prior or concurrent second tumor, except in the following cases:
- •Adequately treated basal cell or squamous cell carcinoma (adequate wound healing required prior to enrollment);
- •Carcinoma in situ of cervical or breast cancer with no signs of recurrence for at least 3 years prior to study after curative treatment;
- •The primary malignancy has been completely resected and in complete remission for ≥5 years.
- •13.Pregnant or lactating women;
- •14.Patients who have a history of or currently have T-cell tumors;
- •15. have active neuroautoimmune or inflammatory disorders (e.g. Guillian-Barre syndrome, AMyotrophic lateral sclerosis);
- •16.Other conditions, such as compliance, that the investigator considers should not be included in this clinical trial.
结局指标
主要结局
Safety by Common Terminology Criteria for Adverse Events (CTCAE) V5.0
时间窗: In CAR-T cells infusion, up to 52 weeks.
The type, frequency, severity, and duration of adverse events as a result of EGFR/B7H3 CAR-T cells infusion will be summarized
次要结局
- Objective Response Rate (ORR)(In CAR-T cells infusion, up to 52 weeks.)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple MyelomaMultiple MyelomaNCT05549973Institute of Hematology & Blood Diseases Hospital, China32
尚未招募
不适用
Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic CholangiocarcinomaIntrahepatic CholangiocarcinomaNCT06313554Fudan University63
进行中（未招募）
2 期
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard TherapyColorectal CancerNCT05435313Fudan University39
招募中
1 期
U87 CAR-T in Patients With Advanced Head and Neck TumorsNasopharynx CancerHead and Neck CancerNCT06614686Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd20
尚未招募
1 期
MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid TumorsNCT05344976Peking University12